抗体
试剂盒
多肽
探针
蛋白
组织芯片
产品中心
Product Center
Research Grade Mirikizumab
All
TD-HV466056_1.jpg
- Catalog： TD-HV466056
- Clonality： mAb
- Application： Research Grade Biosimilar
- Synonyms： LY-3074828, CAS: 1884201-71-1
-
规格：
1mg
-
价格：
¥询价
定制服务咨询
Research Grade Mirikizumab
| Catalog No. | TD-HV466056 |
|---|---|
| Species reactivity | Human |
| Applications | Research Grade Biosimilar |
| Host species | Humanized |
| Isotype | IgG4-kappa |
| Expression system | Mammalian Cells |
| Species | Human |
| Clonality | Monoclonal |
| Target | SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19 |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | Q9NPF7 |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternate Names | LY-3074828, CAS: 1884201-71-1 |
| Background | Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease. |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|
|
Detects IL23A in indirect ELISAs. |